Bottom line
Tesamorelin + Ipamorelin is a direct-description market name with unusually high formulation variance. Observed listings claim 6/2, 5/5, 10/3, 10/5, or 5/3 mg. The name therefore identifies a component pairing but not a standardized ratio. No published study of the co-formulated marketed blend was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Bio Longevity Labs (2026) | Tesamorelin, Ipamorelin | 6 / 2 mg or 10 / 3 mg | Vendor-declared; identity and contents not independently verified |
| Core Peptides (2026) | Tesamorelin, Ipamorelin | 5 / 5 mg or 10 / 5 mg | Vendor-declared market observation |
| Ameano Peptides (2026) | Tesamorelin, Ipamorelin | 5 / 3 mg | Vendor-declared market observation |
The observed tesamorelin-to-ipamorelin mass ratio spans from 1:1 to more than 3:1. These are descriptive labels, not evidence that a ratio was optimized or approved.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| Tesamorelin | See component monograph; product-specific approved-label facts do not transfer to this mixture | None identified for this marketed blend | None identified |
| Ipamorelin | See component monograph | None identified for this marketed blend | None identified |
Combination-specific studies
No published peer-reviewed study testing the exact co-formulated Tesamorelin + Ipamorelin products was identified. Evidence or labeling for tesamorelin alone does not validate a seller-created mixture.
Safety and interaction uncertainties
No combination-specific human safety, interaction, pharmacokinetic, or toxicology dataset was identified.
Wide ratio variance means the pairing name does not identify a reproducible formulation.
A fixed mixture prevents independent adjustment and complicates attribution of unexpected effects.
Identity, purity, sterility, and co-formulation stability cannot be inferred from listings.
Regulatory and product-quality notes
Tesamorelin has product- and indication-specific regulatory history described in its monograph; that status does not extend to this combination.
Ipamorelin's status and the combination's status must be assessed separately.
The cited pages are low-quality market observations, not evidence of an approved fixed combination.
Evidence gaps
No combination-specific controlled study
No ratio standard
No independent content comparison across listings
No published co-formulation compatibility or stability data
Sources
Bio Longevity Labs. Tesamorelin + Ipamorelin market listings. https://biolongevitylabs.com/ accessed 2026-08-08.
Core Peptides. Tesamorelin + Ipamorelin market listings. https://corepeptides.com/ accessed 2026-08-08.
Ameano Peptides. Tesamorelin + Ipamorelin market listing. https://ameanopeptides.com/ accessed 2026-08-08.